News

Clinical Trials Arena48m
Filament Health to supply psilocybin for two Phase II studies
Filament Health has collaborated with UCL to provide its botanical psilocybin drug candidate, PEX010, for two Phase II research studies.
The Manila Times26m
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
Session Topic is the Innovation and Current Directions in Military Suicide Prevention, Research, and ProgramsPresentation ...
The Malaysian Reserve26m
South Rampart Pharma Announces New Study in Neurobiology of Pain Demonstrating How SRP-001 Delivers Central, Non-Toxic Pain Relief
Study highlights novel epigenomic modulation in the central nervous system as a key mechanism for SRP-001's analgesic effects ...